Peptide Therapy for Autoimmune Conditions in Florida

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: August 27, 2026

Key Takeaways for Autoimmune Peptide Therapy

• Supervised peptide therapy combines clinician-prescribed peptides, lab monitoring, and rheumatologist coordination to reduce inflammation and support gut-barrier repair.¹
• No published human randomized controlled trials show peptides reversing autoimmune disease. Peptides serve only as adjunctive support alongside prescribed medications.
• The most relevant peptides, including BPC-157, TB-500, Thymosin Alpha-1, KPV, and GHK-Cu, are selected and stacked based on individual labs, disease activity, and gut-health status.
• Risks stem mainly from unregulated sourcing. Mirror Plastic Surgery mitigates these through batch-specific COAs, HPLC/LC-MS testing, and baseline-plus-follow-up lab panels.
• Patients in Florida seeking medically supervised peptide therapy can book a consultation at Mirror Plastic Surgery to receive a personalized, lab-driven protocol.

How Peptides Fit Into Autoimmune Treatment

No published human randomized controlled trial demonstrates that any peptide reverses an autoimmune disease. Current evidence supports an adjunctive role. Peptides may reduce inflammatory burden, support immune regulation, and improve gut-barrier integrity alongside prescribed DMARDs, biologics, and specialist care.¹

Evidence grades for the three most studied peptides in autoimmune-adjacent applications are as follows.

• Thymosin Alpha-1 (A-): Thymosin alpha-1 has been tested across 8,075 patients in clinical trials and approved in over 35 countries as Zadaxin for hepatitis B and immune deficiency. A 2016 study found altered serum thymosin α1 levels in patients with psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus. These findings suggest a regulatory role. It activates TLR2/TLR9 on dendritic cells and expands regulatory T cells. No randomized controlled trial specifically targeting autoimmune indications has been published.
• BPC-157 (B-): BPC-157 has over 30 animal studies (primarily from one research group) documenting gut-healing effects via growth-factor upregulation, angiogenesis, and nitric oxide modulation, including in TNBS and DSS colitis models. No human randomized controlled trial has been published for any autoimmune indication.
• KPV (C+): This three-amino-acid fragment of alpha-MSH inhibits NF-kB nuclear translocation via the PepT1 transporter, reducing TNF-alpha, IL-6, and IL-1beta. In DSS colitis mouse models, oral KPV has been shown to reduce colitis severity and inflammation. Human clinical trials are absent.

Immune modulation carries real risk during active flares. Patients must loop in their rheumatologist before initiating any immune-active peptide and must never discontinue prescribed autoimmune medications without specialist approval.

Schedule a lab review with Ellie to determine whether peptide therapy is appropriate alongside your current treatment plan.

Choosing Peptides for Autoimmune Inflammation and Gut Repair

Peptides serve as adjunctive support, so the right combination depends on your inflammatory profile and gut-health status. No single peptide is universally optimal. Ellie Pranckevicius builds stacks based on individual lab results, disease activity, and gut-health status.

The five peptides most relevant to autoimmune inflammation and gut repair include the following.

• BPC-157: Targets gut-barrier integrity, mucosal healing, and systemic inflammation.¹ A 2025 systematic review of 36 studies found consistent gut-healing signals in preclinical models by stabilizing tight junctions and counteracting NSAID-induced damage. Clinicians frequently stack BPC-157 with oral KPV for combined barrier-repair and anti-inflammatory effects in IBD or ulcerative colitis.
• TB-500 (Thymosin Beta-4): Addresses soft-tissue inflammation and wound repair.¹ Mirror Plastic Surgery includes TB-500 in the Glow Stack alongside BPC-157 and GHK-Cu for systemic inflammation reduction.
• Thymosin Alpha-1: Promotes T-cell maturation and Th1 polarization.¹ Standard protocol is 1.6 mg subcutaneously twice weekly for 6–12 months in systemic immune-modulation indications. Ellie often pairs Thymosin Alpha-1 with KPV or BPC-157 for gut-specific immune issues. Thymosin Alpha-1 supports systemic immune restoration, while the others target local anti-inflammatory or barrier-healing effects.
• KPV: Suppresses NF-kB activation and reduces pro-inflammatory cytokines, showing effects comparable to mesalamine in preclinical colitis models.¹ Oral bioavailability allows gut-targeted delivery. KPV is relevant for ulcerative colitis, IBD, and mast-cell activation syndrome.
• GHK-Cu (Copper Peptide): Supports collagen and elastin production and reduces systemic inflammation.¹ Ellie uses GHK-Cu individually or as part of the Glow Stack for skin, hair, and nail health alongside anti-inflammatory goals.

A 2026 review in Frontiers in Nutrition describes gut microbiota-targeted bioactive peptides as most effective when paired with prebiotics, probiotics, or polyphenols rather than used in isolation. Mirror Plastic Surgery protocols reflect this finding. Ellie pairs peptide stacks with dietary changes, pre- and probiotic support, stress management, and sleep support per the Peptide Association’s 2026 guidance.

Risks and Red-Flag Labs for Autoimmune Peptide Therapy

The primary risks of peptide therapy relate to unregulated sourcing and lack of medical supervision, not the molecules alone. Research-grade peptides lack FDA-recognized purity, potency, or sterility standards; independent testing has documented underdosing below 50% of label, overdosing, and sequence contamination.

Clinical risks specific to autoimmune patients include immune overstimulation during active flares, interactions with DMARDs or biologics, and metabolic shifts detectable only through lab monitoring. Red-flag lab results requiring immediate protocol cessation fall into three categories. Metabolic markers such as fasting glucose above 126 mg/dL or HbA1c above 6.5% signal glucose dysregulation that peptides may be worsening. Organ-function markers include liver enzymes (AST or ALT) more than three times the upper limit of normal and creatinine rising more than 50% above baseline, which indicate hepatic or kidney stress. Pancreatic enzymes (amylase or lipase) more than three times the upper limit of normal suggest acute inflammation that contraindicates continued therapy.

FDA Actions and a Safe Peptide Clinic Checklist

On April 7, 2026, the FDA issued warning letters dated March 31, 2026, to seven companies, including Gram Peptides, Prime Sciences, Lovega, FormPour, Guangzhou Huli Technology, Mile High Compounds, and PekCura Labs, for selling unapproved peptides such as retatrutide, tirzepatide, and semaglutide. Enforcement remedies cited include seizure, injunction, and criminal referral. The FDA states that selling lyophilized peptides alongside bacteriostatic water for injection demonstrates intended human use, which overrides “research use only” disclaimers.

Separately, The FDA Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, and several other peptides on July 23–24, 2026 for possible addition to the 503A compounding bulks list. This review may further formalize quality standards for supervised clinical use.

Use the following checklist when evaluating any peptide provider.

• Batch-specific COAs with lot numbers traceable to individual production runs, not shared product-line documents
• Third-party HPLC purity testing above 99%, LC-MS identity confirmation, and LAL endotoxin testing at or below 5.0 EU/mg
• ISO/IEC 17025 accreditation on the testing laboratory’s COA, with test dates within 60 days of purchase
• Baseline lab panel ordered before the first dose
• Rheumatologist or specialist coordination documented in the care plan
• No vendor that cannot specify the batch identifier prior to purchase

Peptide Therapy Options for Tampa and St. Petersburg Patients

Tampa-area patients can choose from high-volume telemedicine platforms, local clinics, and concierge practices. The table below compares provider attributes relevant to autoimmune patients. Mirror Plastic Surgery data comes from the practice’s documented protocols. Competitor attributes reflect general characteristics of high-volume and telemedicine clinic models without naming specific providers.

Attribute	Mirror Plastic Surgery	High-Volume Clinic	Online Peptide Retailer
Concierge Follow-Up	24/7 direct text access to Ellie Pranckevicius, with scheduled telemedicine available	Typically scheduled appointments only, with limited between-visit access	None, no clinical follow-up provided
Lab Requirements	Baseline laboratory evaluation and ongoing monitoring	Variable, may offer baseline labs but ongoing monitoring is inconsistent	None, no lab requirements or monitoring
24/7 Support	Yes, direct text line to Ellie	Generally no, after-hours support often limited to urgent care referral	No clinical support of any kind
Sourcing Verification	Batch-specific COAs with HPLC, LC-MS, and LAL endotoxin testing from reputable compounding suppliers	Variable, COA availability and batch specificity not standardized	No FDA oversight, independent testing has documented underdosing below 50% of label and sequence contamination

How Ellie Provides Concierge Peptide Care at Mirror Plastic Surgery

Ellie Pranckevicius, FNP-BC, leads all peptide therapy at Mirror Plastic Surgery. She is a board-certified Family Nurse Practitioner with a Bachelor’s in Health Science from Boston University and a Master’s in Nursing from the University of South Florida. Her four years of critical-care experience in the Neuroscience ICU at Tampa General Hospital inform her safety-first approach. Her dual background in esthetician training and advanced nursing helps her connect aesthetic goals with sound clinical science.

Every patient begins with a 30–60 minute consultation that covers full medical history, current medications, disease activity status, and lab results. If baseline labs are not available, Ellie orders them before any protocol begins. For autoimmune patients, this panel includes CBC with differential, CMP, lipid panel, HbA1c, fasting insulin, thyroid panel, CRP, and ESR, with lymphocyte subsets added for immune-peptide protocols.

Rheumatologist coordination is built into the process. Rheumatologist coordination follows the protocol outlined earlier: Ellie shares the proposed adjunctive role, the peptide’s subcutaneous route from a licensed 503A pharmacy, the patient’s current disease activity, and the full medication list with the treating specialist. Peptides are never positioned as a replacement for specialist care.

The entire process, including consultation, protocol design, prescription, and shipping, is available in-person at Mirror Plastic Surgery’s St. Petersburg location or remotely across Florida and the broader United States. Ellie discusses post-treatment maintenance expectations at the outset. Benefits diminish when protocols stop, so she designs maintenance phases to support outcomes over time.

Start your baseline assessment and receive a protocol tailored to your autoimmune profile.

Frequently Asked Questions

Which Lab Markers Ellie Monitors for Autoimmune Peptide Therapy

Before any protocol begins, Ellie reviews or orders a baseline panel that includes a complete blood count with differential, comprehensive metabolic panel, fasting glucose, HbA1c, fasting insulin, lipid panel, thyroid function (TSH, Free T4, Free T3), CRP, and ESR. For immune-modulating peptides such as Thymosin Alpha-1 or KPV, lymphocyte subsets (CD4+ T cells, CD8+ T cells, CD4/CD8 ratio, NK cells) and immunoglobulins (IgG, IgA, IgM) are added. Follow-up panels are scheduled at 4–6 weeks and then every 3–6 months for longer protocols. Any result crossing the red-flag thresholds described earlier, such as the liver enzyme or creatinine limits, triggers immediate protocol review.

How Ellie Coordinates With Your Rheumatologist

Peptide therapy at Mirror Plastic Surgery remains adjunctive. The coordination process described in the Concierge Care section ensures all providers stay informed. Ellie does not recommend starting a new peptide during an active flare. The protocol is reassessed only once disease activity returns to baseline with specialist approval.

What Happens if You Stop Peptide Therapy

Benefits from peptide therapy do not remain permanent once a protocol ends. When the inflammation that was being modulated is no longer managed, it often returns toward its prior state.¹ For autoimmune patients, this pattern means that maintenance protocols are usually necessary to sustain reductions in inflammatory markers and symptom burden. Ellie discusses realistic maintenance expectations during the initial consultation and designs protocols with long-term sustainability in mind. She schedules reassessment of labs and symptom diaries to guide dose adjustments over time.

FDA Status of Peptides Used at Mirror Plastic Surgery

Most peptides used in wellness and autoimmune-adjacent protocols, including BPC-157, KPV, TB-500, and GHK-Cu, are not FDA-approved for any autoimmune indication. Thymosin Alpha-1 holds international approval as Zadaxin (mentioned earlier) but remains unapproved by the FDA in the United States. Mirror Plastic Surgery sources peptides from compounding suppliers with batch-specific Certificates of Analysis verified through HPLC purity testing, LC-MS identity confirmation, and LAL endotoxin assays. This sourcing standard creates a critical safety distinction from unregulated online retailers, where independent testing has documented significant quality failures. The FDA’s March 31, 2026 warning letters to seven peptide sellers highlight the real enforcement risk of purchasing from unverified sources.

Remote Peptide Therapy Access Outside St. Petersburg

Patients can receive peptide therapy remotely if they live outside St. Petersburg. Mirror Plastic Surgery offers the full consultation, protocol design, prescription, and shipping process across Florida and throughout the United States, including Hawaii and Alaska. Consultations take place via telemedicine, and Ellie remains accessible by direct text for ongoing support, refill requests, and questions between appointments. Lab work can be ordered through local draw sites and reviewed remotely before any protocol begins. Patients outside the Tampa Bay area receive the same concierge-level attention as those seen in person at the St. Petersburg clinic.

Next Steps for Autoimmune Peptide Care in Florida

Floridians managing autoimmune conditions face a clear choice in 2026. They can purchase unregulated online peptides with documented quality failures and active FDA enforcement, or they can pursue medically supervised, batch-verified therapy coordinated with their specialist team. Mirror Plastic Surgery’s concierge model, which includes 30–60 minute consultations, baseline and ongoing lab monitoring, batch-specific COA verification, rheumatologist coordination, and 24/7 direct access to Ellie Pranckevicius, addresses each dimension of that risk.

Get your personalized peptide protocol at Mirror Plastic Surgery in St. Petersburg, designed around your autoimmune profile and long-term health goals.

Disclaimer: Peptide therapies are not FDA-approved to diagnose, treat, or cure autoimmune diseases. Always coordinate with your rheumatologist before initiating any peptide protocol. This content is for educational purposes only and does not constitute medical advice.

---